These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

964 related items for PubMed ID: 20547248

  • 1. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
    Lindfors K, Mäki M, Kaukinen K.
    Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248
    [Abstract] [Full Text] [Related]

  • 2. Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits.
    Stenman SM, Lindfors K, Korponay-Szabo IR, Lohi O, Saavalainen P, Partanen J, Haimila K, Wieser H, Mäki M, Kaukinen K.
    BMC Immunol; 2008 Feb 29; 9():6. PubMed ID: 18312620
    [Abstract] [Full Text] [Related]

  • 3. A role for anti-transglutaminase 2 autoantibodies in the pathogenesis of coeliac disease?
    Lindfors K, Kaukinen K, Mäki M.
    Amino Acids; 2009 Apr 29; 36(4):685-91. PubMed ID: 18594945
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Usefulness of small-bowel mucosal transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease.
    Koskinen O, Collin P, Lindfors K, Laurila K, Mäki M, Kaukinen K.
    J Clin Gastroenterol; 2010 Aug 29; 44(7):483-8. PubMed ID: 19779364
    [Abstract] [Full Text] [Related]

  • 7. Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits.
    Salmi TT, Collin P, Korponay-Szabó IR, Laurila K, Partanen J, Huhtala H, Király R, Lorand L, Reunala T, Mäki M, Kaukinen K.
    Gut; 2006 Dec 29; 55(12):1746-53. PubMed ID: 16571636
    [Abstract] [Full Text] [Related]

  • 8. Intestinal transglutaminase 2 specific antibody deposits in non-responsive coeliac disease.
    Koskinen O, Lindfors K, Collin P, Peräaho M, Laurila K, Woolley N, Partanen J, Mäki M, Kaukinen K.
    Dig Liver Dis; 2010 Oct 29; 42(10):692-7. PubMed ID: 20409763
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.
    Rauhavirta T, Hietikko M, Salmi T, Lindfors K.
    Clin Rev Allergy Immunol; 2019 Aug 29; 57(1):23-38. PubMed ID: 27263022
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Transglutaminase 2 in celiac disease: minireview article.
    Caputo I, D'Amato A, Troncone R, Auricchio S, Esposito C.
    Amino Acids; 2004 Jul 29; 26(4):381-6. PubMed ID: 15290344
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tissue transglutaminase--the key player in celiac disease: a review.
    Reif S, Lerner A.
    Autoimmun Rev; 2004 Jan 29; 3(1):40-5. PubMed ID: 14871648
    [Abstract] [Full Text] [Related]

  • 16. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management.
    Schuppan D, Dennis MD, Kelly CP.
    Nutr Clin Care; 2005 Jan 29; 8(2):54-69. PubMed ID: 16013224
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
    Paolella G, Lepretti M, Barone MV, Nanayakkara M, Di Zenzo M, Sblattero D, Auricchio S, Esposito C, Caputo I.
    Amino Acids; 2017 Mar 29; 49(3):541-550. PubMed ID: 27613408
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.